MRK

Merck & Co Inc

Jul 16 • 04:00PM ET

82.43

Dollar change +0.91
Percentage change 1.12	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD SPY IVV VTV XLV VIG VYM DGRO

Scroll to Statements

Index	DJIA, S&P 500	P/E	12.00	EPS (ttm)	6.87	Insider Own	0.07%	Shs Outstand	2.52B	Perf Week	-1.53%
Market Cap	206.98B	Forward P/E	8.46	EPS next Y	9.75	Insider Trans	-0.19%	Shs Float	2.51B	Perf Month	0.88%
Enterprise Value	232.56B	PEG	1.01	EPS next Q	2.03	Inst Own	80.29%	Short Float	1.40%	Perf Quarter	4.12%
Income	17.43B	P/S	3.25	EPS this Y	15.79%	Inst Trans	0.81%	Short Ratio	2.20	Perf Half Y	-18.37%
Sales	63.78B	P/B	4.29	EPS next Y	10.04%	ROA	15.78%	Short Interest	35.09M	Perf YTD	-17.14%
Book/sh	19.21	P/C	22.18	EPS next 5Y	11.83%	ROE	39.31%	52W High	129.03 -36.12%	Perf Year	-35.48%
Cash/sh	3.72	P/FCF	12.15	EPS past 3/5Y	9.42% 12.04%	ROIC	21.31%	52W Low	73.31 12.44%	Perf 3Y	-12.59%
Dividend Est.	3.12 (3.79%)	EV/EBITDA	8.72	Sales past 3/5Y	9.36% 6.55%	Gross Margin	74.68%	Volatility	2.22% 2.38%	Perf 5Y	12.72%
Dividend TTM	3.20 (3.88%)	EV/Sales	3.65	EPS Y/Y TTM	654.93%	Oper. Margin	34.71%	ATR (14)	1.95	Perf 10Y	50.74%
Dividend Ex-Date	Jun 16, 2025	Quick Ratio	1.16	Sales Y/Y TTM	4.40%	Profit Margin	27.33%	RSI (14)	55.35	Recom	1.84
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.41	EPS Q/Q	7.20%	SMA20	1.77%	Beta	0.40	Target Price	103.05
Payout	46.32%	Debt/Eq	0.72	Sales Q/Q	-1.20%	SMA50	3.96%	Rel Volume	0.72	Prev Close	81.52
Employees	75000	LT Debt/Eq	0.69	Earnings	Jul 29 BMO	SMA200	-10.28%	Avg Volume	15.95M	Price	82.43
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.09% 1.24%	Trades		Volume	11,514,778	Change	1.12%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115

Show Previous Ratings

Today 12:45PM	Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy. (Barrons.com)
11:27AM	Johnson & Johnson shares jump after forecasting sales boost and milder tariff impact (Financial Times)
10:15AM	Grignard Reagents Global Market Forecast Report 2025-2030 \| Emergence of Green Chemistry and Sustainable Practices, & Rising Demand in Asia-Pacific Driving Multi-Billion Opportunities (GlobeNewswire)
09:30AM	Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet (Zacks)
08:41AM	Will Increased Expenses Affect Bristol Myers' Performance? (Zacks)
08:39AM	Loading…
08:39AM	How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results? (Zacks)
08:30AM	Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors (Business Wire)
07:00AM	Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment (GlobeNewswire)
Jul-15-25 07:23PM	Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals (Bloomberg)
05:50PM	Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
02:05PM	Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer (Insider Monkey)
12:54PM	Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention (Zacks)
12:09PM	Stocks Mixed as T-Note Yields Rise (Barchart)
08:54AM	How Will Pfizer's Oncology Drugs Perform in Q2 Earnings? (Zacks)
07:08AM	Cancer drugmaker LaNova to sell to Chinas Sino Biopharm (BioPharma Dive)
07:00AM	Loading…
07:00AM	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA (GlobeNewswire)
06:31AM	Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (BioPharma Dive)
Jul-14-25 01:14PM	Merck to Acquire Verona for $10 Billion, Targeting Life Beyond Keytruda (GuruFocus.com)
11:18AM	The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team (Zacks)
10:23AM	MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth? (Zacks)
09:31AM	Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill (Business Wire)
09:00AM	HER2+ Gastric Cancer Market Analysis and Forecast Report 2025-2035: AstraZeneca, Merck, and Roche Lead Innovation in HER2+ Gastric Cancer Therapies (GlobeNewswire)
08:51AM	Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now. (Barrons.com)
01:30AM	Biotech Stocks Are Ready to Rebound. 3 to Watch Now. (Barrons.com)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
07:01AM	Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs. (The Wall Street Journal)
05:30AM	Will Trumps 200% tariff threat on pharma really materialize? (Investing.com)
Jul-12-25 02:34PM	Merck & Co., Inc. (MRK)'s CEO Thinks He's Got $50 Billion Of New Drugs, Says Jim Cramer (Insider Monkey)
09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
04:56PM	Loading…
Jul-11-25 04:56PM	Big pharma's multiple looming patent cliffs: What to know (Yahoo Finance Video)
04:56PM	Top Analyst Reports for Microsoft, Alibaba & Merck (Zacks)
12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
10:41AM	MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success (Zacks)
08:19AM	Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? (Zacks)
07:15AM	With Verona deal, Merck wagers on strength of lung drugs patents (BioPharma Dive)
05:36AM	2 Top Stocks Down 16% and 17% This Year to Buy and Hold (Motley Fool)
Jul-10-25 04:45PM	FDA Approves BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health (Business Wire)
02:59PM	Pod Digital Media Celebrates Seven Years of Connecting Brands Authentically to Growth Audiences (Business Wire)
01:47PM	Veteran analyst sends bold message on Palantir stock target (TheStreet)
11:40AM	Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration (Insider Monkey)
09:47AM	Alcohol Related Liver Disease Market Forecast, 2025-2035 \| Personalized Medicine Transforming ARLD Treatment Landscape (GlobeNewswire)
06:59AM	Trump Says Powell's Fed Job Is Easy. Why Nvidia, Bitcoin, Market Rally Say Otherwise and 5 Other Things to Know Today. (Barrons.com)
06:45AM	U.S. FDA Accepts New Drug Application for Mercks Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection (Business Wire)
04:57AM	Merck agrees to acquire Verona Pharma for $10bn (Pharmaceutical Technology)
04:04AM	Zacks Investment Ideas feature highlights: QQQ, IWM, SBET, CRCL, COIN, AES, MRK and VRNA (Zacks)
Jul-09-25 06:35PM	Podcast: Trump Sends More Tariff Letters; Nasdaq Climbs to Record (The Wall Street Journal)
05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
05:03PM	Merck will have 'a lot more work to do' after Verona deal (Yahoo Finance Video)
04:16PM	How major US stock indexes fared Wednesday, 7/9/2025 (Associated Press Finance)
04:13PM	Stocks to Watch Wednesday: Freeport-McMoRan, AES, Merck, Fair Isaac (The Wall Street Journal)
04:09PM	Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma (Investor's Business Daily)
02:47PM	Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps (Benzinga)
01:45PM	Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade (Reuters)
01:19PM	Trump's newest tariffs, Merck & Verona, X CEO resigns (Yahoo Finance Video)
01:15PM	Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal (MarketWatch)
12:55PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
12:29PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:07PM	Merck to Buy Verona Pharma for Around $10 Billion (Bloomberg)
12:05PM	Top Stock Movers Now: Nvidia, AES, WPP, and More (Investopedia)
11:17AM	What You Need To Know Ahead of Merck's Earnings Release (Barchart)
10:36AM	Merck to Buy Verona Pharma in $10 Billion Deal (The Wall Street Journal)
10:11AM	Merck Is Buying Lung-Disease Biotech in $10 Billion Deal (Barrons.com)
10:04AM	Verona Phama Stock Soars to All-Time High as Merck Buys Firm for $10B (Investopedia)
09:46AM	Pharma latest: Merck to acquire Verona, Trump pharma tariffs (Yahoo Finance Video)
09:34AM	Tariff Turbulence and Overbought Tech Mark Post-Holiday Trading (Zacks)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:20AM	Will Recent Label Expansions of Opdivo Help BMY Gain Momentum? (Zacks)
09:19AM	Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck (Zacks)
09:19AM	GSK's Specialty Medicines Unit on a Strong Footing: Here's Why (Zacks)
09:10AM	Stock Market Today: Dow Jones Index Rises Ahead Of Fed Minutes; Microsoft Climbs On Upgrade (Live Coverage) (Investor's Business Daily)
09:09AM	UBS Affirms Merck & Co's (MRK) 'Buy' Rating on HPV Vaccine Prospects (Insider Monkey)
08:40AM	Trump Unleashes Tariff Tsunami: Copper at 50%, Pharma Faces 200% -- Markets Rattle (GuruFocus.com)
07:48AM	Trump's tariffs target copper, pharma, Merck to acquire Verona: 3 Things (Yahoo Finance Video)
07:48AM	Merck dives into COPD treatments with $10 billion purchase of Verona Pharma (MarketWatch)
07:42AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:29AM	Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From? (The Wall Street Journal)
07:14AM	Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck. (Barrons.com)
07:06AM	Merck spends $10 billion for Verona, gaining access to its COPD medication (Associated Press Finance)
06:39AM	Merck to acquire Verona Pharma for $10 billion (Reuters)
06:30AM	Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade (Business Wire)
04:43AM	Biomarkers Market Research Report 2025-2030 \| Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision (GlobeNewswire)
01:09AM	Merck shells out $10 billion for London-based lung therapy firm Verona (Reuters)
Jul-08-25 11:34PM	Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK) (StockStory)
04:20PM	Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio (PR Newswire)
02:18PM	Trump Says Hell Set 50% Copper Tariff, Wait Year on Drug Levies (Bloomberg)
01:31PM	Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months (MarketWatch)
10:43AM	AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth? (Zacks)
10:25AM	Equine Healthcare Market Research and Forecast Report 2025-2034 \| Top Players Drive Innovations, Strategic Collaborations and Product Expansion on the Rise (GlobeNewswire)
09:51AM	Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock? (Zacks)
09:00AM	Impactivize: Shareholders of 30 Companies Worth $13 Trillion Vote Overwhelmingly to Defeat Anti-DEI Proposals (PR Newswire)
08:00AM	Certara Announces Expansion of Clinical Technology Collaboration with Merck (GlobeNewswire)
06:45AM	Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025 (Business Wire)
06:03AM	Analysis: 'Trump Effect' website takes credit for US investment made under Biden (Reuters)
Jul-07-25 09:22AM	Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? (Zacks)
08:52AM	SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca (Zacks)
08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
07:30AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
07:17AM	mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2025: Personalized mRNA Cancer Vaccines Revolutionize Oncology with Neoantigen-Driven Immunotherapy (GlobeNewswire)
Jul-06-25 03:35AM	FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR (Insider Monkey)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience